Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial
收藏NIAID Data Ecosystem2026-03-08 收录
官方服务：
资源简介：
The purpose of this study is through a phase I/II clinical trial to assess the safety and toxicity of intraperitoneally administered MOC31PE immunotoxin, given on the 1.postoperative day after cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for peritoneal metastases from colorectal cancer (CRC).
创建时间：
2014-08-15
